Boston MA 黑色素瘤临床试验
25项针对 黑色素瘤的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
招募中1/2 期
- Call for Information (Investigational Site 0026), Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
招募中1 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
招募中2 期
- Local Institution - 0124, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
招募中2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
招募中1/2 期
- Massachusetts General Hospital, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Tufts Medical Center, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
招募中2 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
招募中1/2 期
- Massachusetts General Hospital Cancer Institute, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
招募中2 期
- Massachusetts General Hospital Cancer Center, Boston
Project: Every Child for Younger Patients With Cancer
招募中观察性研究
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
招募中3 期
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
招募中2/3 期
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
招募中2/3 期
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
招募中3 期
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
招募中1 期
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
招募中1/2 期
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
招募中1/2 期
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
招募中2 期
- Dana Farber Cancer Institute, Boston
其他城市的 黑色素瘤试验
- Houston, TX61 项研究
- New York City, NY41 项研究
- Nashville, TN34 项研究
- Los Angeles, CA34 项研究
- Pittsburgh, PA31 项研究
- St. Louis, MO23 项研究
- Durham, NC22 项研究
- Philadelphia, PA22 项研究
- Tampa, FL21 项研究
- Columbus, OH21 项研究
- Dallas, TX21 项研究
- San Francisco, CA21 项研究
Boston的其他研究
- 乳腺癌110 项研究
- 癌症（所有类型）90 项研究
- 非小细胞肺癌87 项研究
- 肺癌63 项研究
- 结直肠癌62 项研究
- 卵巢癌62 项研究
- 转移性癌症61 项研究
- 前列腺癌56 项研究
- 子宫内膜癌51 项研究
- 抑郁症50 项研究
- 心力衰竭46 项研究
- 多发性骨髓瘤45 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。